The American Cancer Society Cancer Action Network (ACS CAN) and 32 other organizations sent a letter to Congressional leadership urging them to update oversight rules for all diagnostic tests, including laboratory developed tests (LDTs). The groups, which represent patients, scientists, advocates, caregivers, and health care professionals, also want the U.S. Food and Drug Administration (FDA) to play a central role in future oversight of such tests.